T-helper cell type 2 response (Th2 response) (Th2 response)

T-helper cell type 2 (Th2) responses are a specialized component of the adaptive immune system characterized by the differentiation of CD4+ T cells into Th2 cells, which secrete a signature profile of cytokines including IL-4, IL-5, and IL-13 (StatPearls, 'T Helper Cells', 2023). These responses are primarily involved in host defense against extracellular parasites, such as helminths, by inducing IgE antibody production, eosinophil recruitment, and goblet cell hyperplasia (Galli et al., Nature, 2008). In a pathological context, dysregulated Th2 responses lead to 'Type 2 inflammation,' a hallmark of allergic diseases including asthma, atopic dermatitis, and chronic rhinosinusitis (Wenzel, NEJM, 2012). Therapeutic strategies targeting this pathway involve monoclonal antibodies that neutralize specific cytokines or block their receptors, thereby interrupting the inflammatory cascade (Gandhi et al., Nature Reviews Drug Discovery, 2016). Key molecular targets within this response include the IL-4 receptor alpha subunit (IL-4Rα), which is shared by both IL-4 and IL-13 signaling, and IL-5, which is critical for eosinophil survival. Modern biologics like dupilumab and mepolizumab have revolutionized the management of severe type 2-high diseases by specifically inhibiting these components. While effective in treating allergic conditions, the suppression of Th2 responses may increase the risk of parasitic infections and has been associated with specific side effects like conjunctivitis in certain treatments.

Other names

Type 2 immune responseTh2-mediated immunityType 2 inflammationHumoral immune response

Therapeutic modulation of the T-helper cell type 2 response involves the use of monoclonal antibodies to neutralize key cytokines such as IL-5 and IL-13, or to block shared receptor subunits like IL-4Rα, thereby preventing the activation of downstream signaling pathways that drive type 2 inflammation (Gandhi et al., Nature Reviews Drug Discovery, 2016).